We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Rakuten Aspyrian has raised $150 million in a series C round to fund its photoimmunotherapy platform and a phase 3 trial in head and neck cancer, alongside plans to expand its pipeline to include other tumor types, both as a monotherapy and in combination